The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Open accessAbstract
BACKGROUND: Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. METHODS: In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 ratio to receive pembrolizumab or placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks. The patients were stratified into two cohorts according to whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease. Previous adjuvant chemotherapy was permitted if the treatment-free interval was at least 12 months. The primary outcome was progression-free survival in the two cohorts. Interim analyses were scheduled to be triggered after the occurrence of at least 84 events of death or progression in the dMMR cohort and at least 196 events in the pMMR cohort. RESULTS: In the 12-month analysis, Kaplan-Meier estimates of progression-free survival in the dMMR cohort were 74% in the pembrolizumab group and 38% in the placebo group (hazard ratio for progression or death, 0.30; 95% confidence interval [CI], 0.19 to 0.48; P<0.001), a 70% difference in relative risk. In the pMMR cohort, median progression-free survival was 13.1 months with pembrolizumab and 8.7 months with placebo (hazard ratio, 0.54; 95% CI, 0.41 to 0.71; P<0.001). Adverse events were as expected for pembrolizumab and combination chemotherapy. CONCLUSIONS: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone. (Funded by the National Cancer Institute and others; NRG-GY018 ClinicalTrials.gov number, NCT03914612.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Makker, V., Colombo, N., Casado Herráez, A., Santin, A. D., Colomba, E., Miller, D. S., Fujiwara, K., Pignata, S., Baron-Hay, S., Ray-Coquard, I., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2108330 · Cited by 930
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
Self-citationO'Malley, D. M., Bariani, G. M., Cassier, P. A., Marabelle, A., Hansen, A. R., De Jesus Acosta, A., Miller, W. H., Safra, T., Italiano, A., Mileshkin, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01874 · Cited by 516
Ott, P. A., Bang, Y.-J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 506
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476
Self-citationOaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4515 · Cited by 364
Self-citationMiller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., DiSilvestro, P., Pearl, M. L., Argenta, P. A., Powell, M. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01076 · Cited by 351
Self-citationLesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O’Malley, D. M., Samouelian, V., Boni, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003777 · Cited by 338
Self-citationClarke, M. A., Devesa, S. S., Harvey, S. V., & Wentzensen, N. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00151 · Cited by 299
Konstantinopoulos, P. A., Luo, W., Liu, J. F., Gulhan, D. C., Krasner, C., Ishizuka, J. J., Gockley, A. A., Buss, M., Growdon, W. B., Crowe, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01021 · Cited by 224
Endometrial cancer: Not your grandmother's cancer
McAlpine, J. N., Temkin, S. M., & Mackay, H. J. (2016) · Cancer · doi:10.1002/cncr.30094 · Cited by 183
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Roselli, M., Cereda, V., di Bari, M. G., Formica, V., Spila, A., Jochems, C., Farsaci, B., Donahue, R., Gulley, J. L., Schlom, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.27025 · Cited by 182
Clarke, M. A., Devesa, S. S., Hammer, A., & Wentzensen, N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0009 · Cited by 162
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Wang, Z., Till, B. G., & Gao, Q. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331807 · Cited by 148
Multiple Testing in Group Sequential Trials Using Graphical Approaches
Maurer, W., & Bretz, F. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.807748 · Cited by 139
Wan, Y.-L. L., Beverley-Stevenson, R., Carlisle, D., Clarke, S., Edmondson, R. J., Glover, S., Holland, J., Hughes, C. B., Kitchener, H. C., Kitson, S., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.333 · Cited by 122
Self-citationStopping when the experimental regimen does not appear to help
Wieand, S., Schroeder, G. S., & O'Fallon, J. R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131321 · Cited by 91
Antill, Y. C., Kok, P., Robledo, K. P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5501 · Cited by 56
Cited by
FIGO staging of endometrial cancer: 2023
Berek, J. S., Matias‐Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14923 · Cited by 1,000
Westin, S. N., Moore, K., Chon, H. S., Lee, J.-Y., Thomes Pepin, J., Sundborg, M., Shai, A., de la Garza, J., Nishio, S., Gold, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02132 · Cited by 380
FIGO staging of endometrial cancer: 2023
Berek, J. S., Matias-Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e85 · Cited by 262
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
Metadata
- Authors
- Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., Mathews, C., Kavecansky, J., Leath, C. A., Gien, L. T., Hinchcliff, E. M., Lele, S. B., Landrum, L. M., Backes, F., O’Cearbhaill, R. E., Al Baghdadi, T., Hill, E. K., Thaker, P. H., John, V. S., Welch, S., Fader, A. N., Powell, M. A., & Aghajanian, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-06-08
- Volume
- 388
- Issue
- 23
- Pages
- 2159-2170
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4360992337
- Cited by
- 758
- References
- 30
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.